- Home
- Products
- Customized ADCs
- PVRL4
- Anti-PVRL4 (Enfortumab vedotin)-MC-MMAF ADC
Anti-PVRL4 (Enfortumab vedotin)-MC-MMAF ADC (CAT#: ADC-W-2398)
This ADC product is comprised of an anti-PVRL4 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- PVRL4
- Alternative Names
- PVRL4; poliovirus receptor-related 4; poliovirus receptor-related protein 4; LNIR; nectin 4; PRR4; Ig superfamily receptor LNIR; Nectin 4; Nectin-4; poliovirus receptor-related 4; Processed poliovirus receptor-related protein 4; PRR4; pvrl4; PVRL4_HUMAN; OTTHUMP00000029698; Ig superfamily receptor LNIR; EDSS1; nectin-4;
- Target Entrez Gene ID
- 81607
- Target UniProt ID
- P21860
- Overview
- This gene encodes a member of the nectin family. The encoded protein contains two immunoglobulin-like (Ig-like) C2-type domains and one Ig-like V-type domain. It is involved in cell adhesion through trans-homophilic and -heterophilic interactions. It is a single-pass type I membrane protein. The soluble form is produced by proteolytic cleavage at the cell surface by the metalloproteinase ADAM17/TACE. The secreted form is found in both breast tumor cell lines and breast tumor patients. Mutations in this gene are the cause of ectodermal dysplasia-syndactyly syndrome type 1, an autosomal recessive disorder. Alternatively spliced transcript variants have been found but the full-length nature of the variant has not been determined.
- Overview
- Human Anti-PVRL4 IgG1-kappa antibody, Enfortumab vedotin
- Generic name
- Enfortumab vedotin
- Host animal
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD248 (Ontuxizumab)-MC-MMAF ADC (CAT#: ADC-W-808)
- Anti-MUC1 (Sontuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2489)
- Anti-MS4A1-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-619)
- Anti-CEACAM1 (Arcitumomab)-SMCC-DM1 ADC (CAT#: ADC-W-962)
- Anti-TNFRSF8 (Iratumumab)-SPDB-DM4 ADC (CAT#: ADC-W-1887)
- Anti-VEGFA (Bevacizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1931)
- Anti-NRP1 (Vesencumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1679)
- Anti-MUC16 (Sofituzumab)-VC-MMAE ADC (CAT#: ADC-W-427)
- Anti-CEACAM5-Phy-lys-SN-38 ADC (CAT#: ADC-W-472)
- Anti-FOLH1 (MLN591)-thioester-DM1 ADC (CAT#: ADC-W-433)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2398. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2397 | Anti-PVRL4 (Enfortumab vedotin)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2401 | Anti-PVRL4 (Enfortumab vedotin)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2400 | Anti-PVRL4 (Enfortumab vedotin)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2396 | Anti-PVRL4 (Enfortumab vedotin)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2399 | Anti-PVRL4 (Enfortumab vedotin)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-452 | Anti-CD70 (clone 1F6)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-518 | Anti-TM4SF1 ( clone 2A7A)-Mc-LP2 ADC | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
ADC-W-322 | Anti-CD19 (clone hBU12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-493 | Anti-CD19 (clone huB4)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-485 | Anti-EphA2 (clone 1C1)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
CAT# | Product Name | Linker | Payload |
ADC-W-2561 | Anti-MSLN (Anetumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2567 | Anti-MUC16 (Sofituzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
ADC-W-2556 | Anti-CD79B (Polatuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.